Enzymatica AB provided sales guidance for the first quarter of 2020. Due to the Coronavirus outburst (COVID-19) in the beginning of 2020 Enzymatica notes a strong demand of the cold spray ColdZyme during the month of March, which is expected to continue during the coming months. Current order-book and sales for the first quarter indicate a doubling of turnover for First Quarter 2020 compared to First Quarter 2019, which at that time amounted to SEK 13.3 million. As regards to production of ColdZyme contract manufacturers in Europe follow decided production plans, so far without interruptions. However, there is great uncertainty when it comes to the continued development of demand and its effect on production and logistics, which may affect the company’s order-intake and sales.